Merck Picks Up Hanmi’s Dual Agonist Efinopegdutide, But For NASH

Repurposed Promise In Competitive Indication

Hanmi licenses out GLP-1/glucagon receptor dual agonist for NASH to Merck, in a deal worth up to $870m, marking a positive turn for the Korean firm's pipeline after Janssen returned rights last year.

liver
Hanmi’s First Major Licensing Out Deal For Years • Source: Shutterstock

Merck & Co., Inc. (known as MSD outside North America) and Hanmi Pharmaceutical Co., Ltd. have reached an exclusive licensing agreement for the development, manufacture and commercialization of efinopegdutide (formerly HM12525A), Hanmi’s investigational once-weekly glucagon-like peptide-1 (GLP-1)/glucagon receptor dual agonist, for the treatment of non-alcoholic steatohepatitis (NASH), in a deal worth up to $870m.

More from South Korea

More from Focus On Asia